Alto Neuroscience (ANRO) reported second-quarter 2026 financial results and pipeline updates, including plans for an additional Phase 3 trial of ALTO-207 as monotherapy in treatment-resistant depression.
The company reported a net loss of $27.6 million for the quarter ended June 30, 2026, compared with a net loss of $17.7 million a year earlier. Alto said it completed an approximately $100 million financing in July and had pro forma cash of approximately $338 million expected to fund planned operations through 2030.
- Cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026.
- Research and development expenses were $22.1 million, compared with $13.1 million in the prior-year quarter.
- General and administrative expenses were $7.0 million, compared with $5.6 million a year earlier.
- ALTO-207 Phase 2b adjunctive TRD topline data remain expected in the second half of 2027.
- Alto plans to initiate a Phase 3 adjunctive TRD trial in early 2027 and a Phase 3 monotherapy TRD trial in the second half of 2027, pending FDA alignment.
- Topline data are expected in the first half of 2027 for ALTO-300 in major depressive disorder and mid-2027 for ALTO-100 in bipolar depression.
$ANRO Hedge Fund Activity
We have seen 60 institutional investors add shares of $ANRO stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 1,454,821 shares (+218.4%) to their portfolio in Q2 2026, for an estimated $38,392,726
- POINT72 ASSET MANAGEMENT, L.P. removed 1,103,867 shares (-68.7%) from their portfolio in Q1 2026, for an estimated $24,814,930
- SPRUCE STREET CAPITAL LP added 1,102,366 shares (+494.7%) to their portfolio in Q1 2026, for an estimated $24,781,187
- COMMODORE CAPITAL LP added 900,000 shares (+49.4%) to their portfolio in Q1 2026, for an estimated $20,232,000
- ARMISTICE CAPITAL, LLC removed 624,000 shares (-40.6%) from their portfolio in Q1 2026, for an estimated $14,027,520
- AFFINITY ASSET ADVISORS, LLC added 500,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,240,000
- STATE STREET CORP added 486,442 shares (+243.8%) to their portfolio in Q2 2026, for an estimated $12,837,204
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
